Esketamine nasal spray for treatment-resistant depression: A retrospective multicenter real-world cohort study on effectiveness and suicidal outcomes
In real-world clinical setting, ESK NS produces progressive improvements in depressive symptoms and functioning that often consolidating beyond the induction phase, especially during optimization phase.
Authors
- Luís Gutiérrez-Rojas (ORCID: https://orcid.org/0000-0003-0082-2189)
- Jesús García-Jiménez (ORCID: https://orcid.org/0000-0003-1411-2620)
- G. Carretero Merelo
- A. Miller
- A. Martínez Romero
- J. E. Mesones Peral
- D. Nuñez-Arias
Institutions
- Neurosciences Institute (US)
- Instituto de Investigación Biosanitaria de Granada (ES)
- Complexo Hospitalario Universitario A Coruña (ES)
- Hospital Quirón Torrevieja (ES)
Publication Details
- Journal
- Journal of Psychopharmacology
- Published
- 2026-03-21
- DOI
- https://doi.org/10.1177/02698811261430495
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00